The ethics of placebo-controlled trials: methodological justifications
Related Experiment Video
Updated: May 7, 2026

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
Published on: December 14, 2014
Joseph Millum1, Christine Grady
1Department of Bioethics, Clinical Center, National Institutes of Health, 10/1C118, 10 Center Drive, Bethesda, MD 20892, United States; Fogarty International Center, National Institutes of Health, 16/210, Stone House, Bethesda, MD 20892, United States.
Abstract:
The use of placebo controls in clinical trials remains controversial. Ethical analysis and international ethical guidance permit the use of placebo controls in randomized trials when scientifically indicated in four cases: (1) when there is no proven effective treatment for the condition under study; (2) when withholding treatment poses negligible risks to participants; (3) when there are compelling methodological reasons for using placebo, and withholding treatment does not pose a risk of serious harm to participants; and, more controversially, (4) when there are compelling methodological reasons for using placebo, and the research is intended to develop interventions that can be implemented in the population from which trial participants are drawn, and the trial does not require participants to forgo treatment they would otherwise receive. The concept of methodological reasons is essential to assessing the ethics of placebo controls in these controversial last two cases. This article sets out key considerations relevant to considering whether methodological reasons for a placebo control are compelling.
Related Concept Videos
Blinding
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Blind Procedures
The Placebo Effect
Ethics in Research
Clinical Trials
There are four phases in a clinical trial. A phase one...
